Phase II evaluation of interleukin-4 in patients with non-Hodgkinʼs lymphoma: a Southwest Oncology Group Trial
Authors:
- Charles W TaylorCTCharles W Taylor
- Michael LeBlancMLMichael LeBlanc
- Richard I FisherRFRichard I Fisher
- Dennis F MooreDMDennis F Moore
- Ralph W RoachRRRalph W Roach
- Laurence EliasLELaurence Elias
- Thomas P MillerTMThomas P Miller
- 1 October 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 11 (9) , 695-700
Abstract
We performed a phase II, Southwest Oncology Group (SWOG) clinical trial of recombinant human interleukin-4 (rhuIL-4) in patients with previously treated non-Hodgkin's lymphoma (NHL). We studied 18 eligible patients with low-grade and 21 patients with intermediate- or high-grade NHL. All patients had received prior chemotherapy. A protocol amendment after the first four patients reduced the frequency of s.c. rhuIL-4 administration from daily to 3 times per week at 3 microg/kg and limited the number of prior chemotherapy regimens allowed. We documented no complete or partial responses in the low-grade NHL group [0%; 95% confidence interval (CI) 0-19%]. One patient in the intermediate/high-grade NHL group developed a partial response lasting longer than 15 months (5%; 95% CI 0-24%). Median survivals for the low- and intermediate/high-grade NHL groups were 15 and 13 months, respectively. Common toxicities included: arhralgia/myalgia, fatigue/malaise/lethargy, fever, headache, nausea and rigors/chills. Cardiac toxicity, gastrointestinal ulceration and nasal congestion due to rhuIL-4 were not prominent toxicities in our patients. Our previously treated NHL patients tolerated s.c. rhuIL-4 at a dose of 3 microg/kg given 3 times per week, but objective response rarely occurred. Further evaluation of rhuIL-4 in these patient populations does not appear warranted.Keywords
This publication has 15 references indexed in Scilit:
- Interleukin-4 is effective in restoring cytotoxic T cell activity that declines during in vivo progression of a murine B lymphomaCancer Immunology, Immunotherapy, 1997
- Safety Evaluation of Recombinant Human Interleukin-4Clinical Immunology and Immunopathology, 1997
- Phase II Studies of Recombinant Human Interleukin-4 in Advanced Renal Cancer and Malignant MelanomaJournal of Immunotherapy, 1994
- Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteriaInvestigational New Drugs, 1992
- Antiproliferative Effect of Interleukin-4 in B Chronic Lymphocytic LeukemiaJournal of Immunotherapy, 1991
- Signal transduction mechanisms of Ia induction in B cells by interleukin 4 and immunoglobulin receptorsCellular Immunology, 1990
- Cytokine‐mediated modulation of HLA‐class II, ICAM‐1, LFA‐3 and tumor‐associated antigen profile of melanoma cells. comparison with anti‐proliferative activity by RIL1‐β, RTNF‐α, RIFN‐γ, RIl4 and their combinationsInternational Journal of Cancer, 1990
- Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma.Journal of Experimental Medicine, 1988
- HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma.Journal of Clinical Investigation, 1988
- Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins.Proceedings of the National Academy of Sciences, 1988